Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (ANGN) on May 1, 2023. The filing reports on a proposed merger between Angion and Elicio Therapeutics, Inc., a clinical-stage biotechnology company developing immunotherapies for cancer. The Merger Agreement was originally entered into on January 17, 2023. The report also announces that Elicio will present interim Phase 1 data for its investigational cancer vaccine, ELI-002, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Angion or Elicio. This document serves as a current report on corporate events rather than a financial statement.
Material Changes
- Merger Agreement: Angion and Elicio are proceeding with a merger where Elicio will become a wholly owned subsidiary of Angion.
- Clinical Data Announcement: Elicio announced plans to present interim data from the Phase 1 study of ELI-002 in patients with high relapse risk pancreatic and colorectal cancer.
Guidance, Outlook, and Risks
Outlook: The transaction is subject to the satisfaction of conditions described in the Merger Agreement. Investors are urged to read the registration statement on Form S-4, which includes a proxy statement and prospectus, for detailed information regarding the merger.
Risks and Contingencies: The filing notes that the communication does not constitute an offer to sell securities. The merger is contingent upon regulatory approvals and shareholder votes as detailed in the Form S-4.
Investor Verification Checklist
- Review the Form S-4 registration statement filed on April 28, 2023, for full details on the merger terms and risks.
- Verify the interim Phase 1 data presentation for ELI-002 at the 2023 ASCO annual meeting.
- Confirm the status of the merger conditions and shareholder approval requirements.
- Check Angion's website (www.angion.com) or the SEC website for the latest proxy statement and prospectus.